RxDoctor Payments Data

Lynn Wright, MD

Family Medicine · New Paris, PANPI 1386930519

Payments from drug & device makers

$1,046in general payments, 2019–2025

Across 60 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$225
  • AbbVie$141
  • GSK$112
  • Pfizer$108
  • Lilly USA, LLC$63
  • Johnson & Johnson$56
  • plus $341 from 13 others

What the payments were for

  • Food & beverage$1,046100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,046 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$37,868
Medicare patients
113
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$117,191
JardianceEmpagliflozin98$85,080
TradjentaLinagliptin39$51,391
EliquisApixaban70$50,020
XareltoRivaroxaban30$24,538
TrulicityDulaglutide17$23,377
JanuviaSitagliptin Phosphate32$23,347
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,897
BrilintaTicagrelor22$11,811
FarxigaDapagliflozin Propanediol12$8,096
Breo ElliptaFluticasone/Vilanterol14$7,209
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$6,047
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,215
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$4,721
Atorvastatin Calcium319$4,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$17$136,472137 claims
Novo NordiskOzempic$225$117,191105 claims
PfizerEliquis, Dilantin$108$51,69182 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$112$24,91147 claims
Johnson & JohnsonXarelto$56$24,53830 claims
Lilly USA, LLCTrulicity$63$23,37717 claims
MerckJanuvia$15$23,34732 claims
AstraZenecaBrilinta, Farxiga$16$19,90734 claims
AbbVieSynthroid$141$1,54529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in New Paris

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →